GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (NAS:SCYX) » Definitions » Net Cash per Share

SCYNEXIS (SCYNEXIS) Net Cash per Share : $0.51 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is SCYNEXIS Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). SCYNEXIS's Net Cash per Share for the quarter that ended in Dec. 2023 was $0.51.

The historical rank and industry rank for SCYNEXIS's Net Cash per Share or its related term are showing as below:

SCYX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.04   Med: 3.46   Max: 21.16
Current: 3.8

During the past 12 years, the highest Price-to-Net-Cash Ratio of SCYNEXIS was 21.16. The lowest was 1.04. And the median was 3.46.

SCYX's Price-to-Net-Cash is ranked better than
75.19% of 258 companies
in the Drug Manufacturers industry
Industry Median: 7.655 vs SCYX: 3.80

SCYNEXIS Net Cash per Share Historical Data

The historical data trend for SCYNEXIS's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Net Cash per Share Chart

SCYNEXIS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.67 0.90 -0.34 0.51

SCYNEXIS Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -1.36 0.64 0.85 0.51

Competitive Comparison of SCYNEXIS's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SCYNEXIS's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Price-to-Net-Cash falls into.



SCYNEXIS Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

SCYNEXIS's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(74.362-55.45-0)/37.2078
=0.51

SCYNEXIS's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(74.362-55.45-0)/37.2078
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SCYNEXIS  (NAS:SCYX) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


SCYNEXIS Net Cash per Share Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


SCYNEXIS (SCYNEXIS) Business Description

Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
Executives
David C Hastings director C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Brian Philippe Tinmouth director 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Guy Macdonald director C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Ann Hanham director ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Armando Anido director 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Ivor Macleod officer: Chief Financial Officer 3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
Scott Sukenick officer: General Counsel 101 HUDSON STREET, SUITE 3610, JERSEY CITY NJ 07302
Marco Taglietti director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Lawrence R Hoffman officer: Interim CFO C/O COVALENT GROUP, INC., 1275 DRUMMERS LANE, SUITE 100, WAYNE PA 19087
Christine Coyne officer: Chief Commercial Officer 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric Francois officer: Chief Financial Officer C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Gonzalez David Angulo officer: Chief Medical Officer C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713

SCYNEXIS (SCYNEXIS) Headlines

From GuruFocus